NCT06166862 Action Observation and Motor Imagery Therapy in Stroke
| NCT ID | NCT06166862 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Karamanoğlu Mehmetbey University |
| Condition | Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 56 participants |
| Start Date | 2023-12-12 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 56 participants in total. It began in 2023-12-12 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In recent years, motor imagery (MI) and action observation (AO) therapy strategies have been used in rehabilitation programs to increase motor learning in stroke. Visuomotor training strategies such as AO and MI therapy rely on the activity of the mirror neuron system to facilitate motor re-learning. Mirror neurons are activated during the performance of goal-directed actions, also when observing the same action and visualizing the action in the mind. This clinical trial aims to test whether the application of AO and MI treatment in stroke in addition to conventional rehabilitation programs has an additional effect on motor recovery, activities of daily living, and quality of life.
Eligibility Criteria
Inclusion Criteria: * Patients who had a stroke in the last year * Functional Ambulation Classification score 2-5 Exclusion Criteria: * Patients who have had repeated strokes * Patients with neglect * Patients with cognitive dysfunction (those who cannot follow simple verbal instructions) * Patients with severe hearing problems * Patients with severe vision problems * Patients with additional musculoskeletal system pathology that will affect physical performance (such as amputation, severe joint mobility limitation, peripheral nerve damage) * Patients with uncontrolled hypertension and diabetes mellitus * Patients with a history of symptomatic lung disease (such as asthma, chronic obstructive pulmonary disease, emphysema) * Patients with a history of symptomatic cardiac disease (such as coronary artery disease, arrhythmia, heart failure) * Patients with peripheral artery disease
Contact & Investigator
Yurdagul Bahran Mustu, MD.
PRINCIPAL INVESTIGATOR
Karaman Training and Research Hospital
Frequently Asked Questions
Who can join the NCT06166862 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06166862 currently recruiting?
Yes, NCT06166862 is actively recruiting participants. Contact the research team at yurdagulbahran@gmail.com for enrollment information.
Where is the NCT06166862 trial being conducted?
This trial is being conducted at Karaman, Turkey (Türkiye).
Who is sponsoring the NCT06166862 clinical trial?
NCT06166862 is sponsored by Karamanoğlu Mehmetbey University. The principal investigator is Yurdagul Bahran Mustu, MD. at Karaman Training and Research Hospital. The trial plans to enroll 56 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.